Floatz logo

Tisagenlecleucel

B-cell Adult Acute Lymphoblastic Leukemia

Chinese PLA General HospitalCell therapyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the B-cell Adult Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
The First Affiliated Hospital of Soochow University
Phase 3BBB
Fludarabine
The First Affiliated Hospital of Soochow University
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Mayo Clinic
Phase 2BB
Calcium folinate pentahydrate
Mayo Clinic
Phase 3BB
ASPARAGINASE
National Cancer Institute (NCI)
Phase 2BB

View all 39 →

Same molecule, other indications

Tisagenlecleucel is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
Diffuse Large B Cell LymphomaDormant
BB
Indicative ·
64 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →